Want to see ICLR full AI Analyst Report?
ICLR Stock Chart & Stats
$119.68
-$3.85(-1.73%)
At close: 4:00 PM EST
$119.68
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$66.57 - $211.00
Previous CloseN/A
Volume330.38K
Average Volume (3M)954.93K
Market Cap
$13.02B
Enterprise Value$11.33K
Total Cash (Recent Filing)$765.16M
Total Debt (Recent Filing)$3.51B
Price to Earnings (P/E)30.0
Beta0.99
Next Earnings
Jul 29, 2026EPS Estimate
2.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.66
Shares Outstanding76,567,320
10 Day Avg. Volume539,169
30 Day Avg. Volume954,932
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.55
Price to Sales (P/S)1.73
P/FCF Ratio16.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$178.69Price Target Upside49.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)10.63
Revenue Forecast (FY)$8.06B
Bulls Say, Bears Say
Bulls Say
Robust Bookings And BacklogA large, growing backlog and elevated gross bookings create a durable revenue pipeline over coming quarters. Strong win rates across large pharma and biotech (net book-to-bill 1.42x) reduce near‑term cyclicality, supporting utilization and contract conversion as revenue is recognized.
Strong Cash Generation & Improving LeverageHealthy absolute cash flow and falling net debt materially boost financial flexibility. Robust operating cash and FCF fund reinvestment, planned buybacks and debt service, lowering refinancing risk and giving management optionality to invest in growth or return capital over the medium term.
Service Breadth And Strategic InvestmentsTargeted investments in site networks, lab capacity and AI-driven clinical tools strengthen delivery scale, geographic reach and operational efficiency. These structural moves can increase patient access, speed trial delivery and differentiate ICON's service offering over the next several quarters.
Bears Say
Margin CompressionMeaningful declines in gross and EBITDA margins reflect mix shifts to lower‑margin FSP work, higher delivery costs and pass‑through volatility. Persistent margin pressure will constrain free cash flow and reinvestment capacity until full‑service mix and pricing sustainably improve.
Stagnant Revenue GrowthFlat reported revenue and modest CC declines limit operating leverage and make margin recovery harder. Even with strong bookings, cancellations and pass‑through swings challenge convertibility of backlog into sustained top‑line growth over the next several quarters.
Accounting Restatements & Control WeaknessesRestatements and disclosed material weaknesses in internal controls raise regulatory, compliance and credibility risks. This can increase audit and remediation costs, impair investor trust and complicate capital actions or M&A, posing a persistent governance overhang in the medium term.
Icon News
ICLR FAQ
What was Icon Plc’s price range in the past 12 months?
Icon Plc lowest stock price was $66.57 and its highest was $211.00 in the past 12 months.
What is Icon Plc’s market cap?
Icon Plc’s market cap is $13.02B.
When is Icon Plc’s upcoming earnings report date?
Icon Plc’s upcoming earnings report date is Jul 29, 2026 which is in 11 days.
How were Icon Plc’s earnings last quarter?
Icon Plc released its earnings results on Jun 23, 2026. The company reported $2.5 earnings per share for the quarter, beating the consensus estimate of $2.432 by $0.068.
Is Icon Plc overvalued?
According to Wall Street analysts Icon Plc’s price is currently Undervalued.
Does Icon Plc pay dividends?
Icon Plc does not currently pay dividends.
What is Icon Plc’s EPS estimate?
Icon Plc’s EPS estimate is 2.55.
How many shares outstanding does Icon Plc have?
Icon Plc has 76,567,320 shares outstanding.
What happened to Icon Plc’s price movement after its last earnings report?
Icon Plc reported an EPS of $2.5 in its last earnings report, beating expectations of $2.432. Following the earnings report the stock price went up 10.864%.
Which hedge fund is a major shareholder of Icon Plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$178.69 (49.31% Upside)
$178.69 (49.31% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.02%
12-Months-Change
Fundamentals
Return on Equity
5.20%
Trailing 12-Months
Asset Growth
-1.94%
Trailing 12-Months
Company Description
Icon Plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICLR Stock 12 Month Forecast
Average Price Target
$178.69
▲(49.31% Upside)
Technical Analysis
Ownership Overview
― Insiders
36.95% Mutual Funds
5.70% Other Institutional Investors
54.81% Public Companies and
Individual Investors